Supriya Lifescience Ltd Q2 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/e46pq4khetoqveyvhk0mbvyt.pdf

Key Takeaways


The China Shock: What Happened and What's at Stake

Ashish Nayak: "I mean it can happen in the coming month; it can happen 3 months down the line. Only time will tell us. That is something which is not in my hands, not in your hands as well."

Margin Mechanics: Why the Drop Was So Sharp


CMO/CDMO: From Qualification to Commercial Reality


Capacity Build-Out and De-Risking

Rajeev Kumar Jain: "We take this challenge as the opportunity to add more products in our basket with improved efficiencies."

Balance Sheet and Capital Allocation


Guidance & Commitments

CommitmentSpecificsTimeline
China/Europe revenue recoveryLost H1 sales recovered because demand and order book are intact; only logistics resolution neededWhen China lockdowns and Europe uncertainties normalize (no fixed date)
CMO projects to regulatory filingTwo CMO projects cross phase 2 and become ready for regulatory filingQ4 FY23
E block operational~350 KL reactor capacity addedQ1 FY24
Ambernath facilities operationalNew manufacturing block (70 KL) and pilot plant fully operationalQ1 FY24
Total capacityIncreases to 810 KL once two manufacturing blocks are operationalQ1 FY24
Isambe land conversion₹56 crores advance converted to leasehold landComing quarter (Q3 FY23)
Upgraded ETP facilityExpected completionQ4 FY23
CMO/CDMO separate disclosureContribution disclosed as separate line itemWhen activity picks up substantially
Full-year revenue guidanceRevised guidance provided after watching next couple of monthsTowards end of Q3 FY23

Key Metrics

MetricQ2 FY23
Operating revenue₹112 cr, vs ₹150 cr in Q2 FY22
EBITDA margin25%, vs 42% in Q2 FY22
PAT margin15%
H1 FY23 revenue from operations₹213 cr, vs ₹227 cr in H1 FY22
H1 FY23 EBITDA₹60 cr, vs ₹96 cr in H1 FY22
H1 FY23 EBITDA margin28%, vs 42% in H1 FY22
H1 FY23 PAT₹42 cr, 20% of revenue
H1 FY23 PBT₹58 cr
Exports share~79% of sales
Regulated market share22% in H1 FY23, vs 53% in FY22
Gross margin58%, down from 65% sequentially
Revenue gap from China~₹50 cr, for a specific product
Capacity utilization72%
H1 FY23 production volume372 metric tons
New ANDA projects initiated in Q25 for anesthetic, 1 for vitamins, 1 for antihypertensive
CMO/CDMO projects in regulatory submission stage2, expected to file in Q4 FY23
Total capacity once new blocks operational810 KL
Net working capital₹405 cr, vs ₹398 cr
Inventory₹106 cr, ~261 days vs 200 days as on March 22
Receivables₹81 cr, 68 days vs ₹115 cr; decline of ₹34 cr
Cash and bank balance₹190 cr, of which ₹180 cr in fixed deposits
Debt equity0.06
IPO expense apportionment in H1 FY23~₹1.8 cr, apportioned over 5 years
H1 FY23 power expenses₹9.5 cr, vs ₹14 cr for full year FY22
H1 FY23 repairs₹8.5 cr, vs ₹7.5 cr in FY22